Evidence map›Paper›PMID 37740236›Full record

ArticleExperimental hematology & oncology2023

Recent advances and future perspectives in the therapeutics of prostate cancer.

Ganji Lakshmi Varaprasad, Vivek Kumar Gupta, Kiran Prasad, Eunsu Kim, Mandava Bhuvan Tej, Pratik Mohanty, Henu Kumar Verma, Ganji Seeta Rama Raju, Lvks Bhaskar, Yun Suk Huh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Development and In Vitro Evaluation of [International journal of molecular sciences · 2025
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025
    Review
  19. Review
  20. Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ganji Lakshmi Varaprasad *Department of Biological Sciences and Bioengineering, Biohybrid Systems Research Center (BSRC), Inha University, Incheon, 22212, Republic of Korea.
Vivek Kumar Gupta *Department of Biological Sciences and Bioengineering, Biohybrid Systems Research Center (BSRC), Inha University, Incheon, 22212, Republic of Korea.
Kiran Prasad *Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.
Eunsu KimDepartment of Biological Sciences and Bioengineering, Biohybrid Systems Research Center (BSRC), Inha University, Incheon, 22212, Republic of Korea.
Mandava Bhuvan TejDepartment of Health Care Informatics, Sacred Heart University, 5151 Park Avenue, Fair Fields, CT, 06825, USA.
Pratik MohantyDepartment of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.
Henu Kumar VermaDepartment of Immunopathology, Institute of Lungs Health and Immunity, Helmholtz Zentrum, 85764, Neuherberg, Munich, Germany.
Ganji Seeta Rama RajuDepartment of Energy and Materials Engineering, Dongguk University-Seoul, Seoul, 04620, Republic of Korea. gseetaramaraju7@dongguk.edu.
Lvks BhaskarDepartment of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India. lvksbhaskar@gmail.com.
Yun Suk HuhDepartment of Biological Sciences and Bioengineering, Biohybrid Systems Research Center (BSRC), Inha University, Incheon, 22212, Republic of Korea. yunsuk.huh@inha.ac.kr.

Funding

National Research Foundation of Korea 2020R1I1A1A01072635National Research Foundation of Korea 2021R1A5A6002853
6 · The paper itself

Abstract

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness and lethality of PC. The African population is at the highest risk of developing high-grade PC. It can be challenging to distinguish between low-risk and high-risk patients due to the slow progression of PC. Prostate-specific antigen (PSA) is a revolutionary discovery for the identification of PC. However, it has led to an increase in over diagnosis and over treatment of PC in the past few decades. Even if modifications are made to the standard PSA testing, the specificity has not been found to be significant. Our understanding of PC genetics and proteomics has improved due to advances in different fields. New serum, urine, and tissue biomarkers, such as PC antigen 3 (PCA3), have led to various new diagnostic tests, such as the prostate health index, 4K score, and PCA3. These tests significantly reduce the number of unnecessary and repeat biopsies performed. Chemotherapy, radiotherapy, and prostatectomy are standard treatment options. However, newer novel hormone therapy drugs with a better response have been identified. Androgen deprivation and hormonal therapy are evolving as new and better options for managing hormone-sensitive and castration-resistant PC. This review aimed to highlight and discuss epidemiology, various risk factors, and developments in PC diagnosis and treatment regimens.

Indexed as

DiagnosisProstate cancerQuality of lifeRisk factorsTreatment

Identifiers

PMID37740236
PMCPMC10517568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.